Vigneswaran, Hari T. http://orcid.org/0000-0001-9703-2655
Palsdottir, Thorgerdur
Olsson, Henrik
Haug, Erik S.
Picker, Wolfgang
Löffeler, Sven http://orcid.org/0000-0002-3553-2491
Grönberg, Henrik
Eklund, Martin http://orcid.org/0000-0001-5032-5266
Nordström, Tobias http://orcid.org/0000-0003-4915-7546
Funding for this research was provided by:
Vetenskapsrådet
Forskningsrådet om Hälsa, Arbetsliv och Välfärd
Cancerfonden
Article History
Received: 3 June 2020
Revised: 24 September 2020
Accepted: 13 October 2020
First Online: 9 November 2020
Compliance with ethical standards
:
: HG has five prostate cancer diagnostic-related patents pending, has patent applications licensed to Thermo Fisher Scientific, and might receive royalties from sales related to these patents. ME has five prostate cancer diagnostic-related patents pending. Karolinska Institutet collaborates with Thermo Fisher Scientific in developing the technology for the Stockholm3 test. The other authors declare that they have no conflict of interest.